Multiple-dose study of imipenem/cilastatin in patients with end-stage renal disease undergoing long-term hemodialysis

Berman, Steven; Sugihara, Jared; Nakamura, J; Kawahara, K; Wong, Eugene G.C.; Musgrave, James; Wong, Livingston; Siemsen, Arnold M.

doi:10.1016/0002-9343(85)90112-3

Cited by 26 publications

(9 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[5][6][7][8][9][10][11][12] In vitro studies have shown that imipenemhasexcellentactivityagainst bothgram-positive and gram-negative bacteria, aerobes as well as anaerobes. 1,6,8,[13][14][15][16][17] Almost all previous studies were confined to bacterial strains isolated in North America or Europe, where microorganisms are known to be more susceptible to commonly used antibiotics than the strains isolated in Asia, Africa, and South America.…”

Section: Accepted For Publication 25 September 1988mentioning

confidence: 99%

In Vitro Susceptibility of Relatively Resistant Bacteria to Imipenem

Qadri

Al-Hosain

1989

Ann Saudi Med

View full text Add to dashboard Cite

In vitro activity of imipenem was tested against 965 clinical isolates from a major referral center in Saudi Arabia. Many of these strains were highly resistant to commonly used antibiotics, such as ampicillin, cephalosporins, gentamicin, piperacillin, and ticarcillin. All the 727 isolates of Enterobacteriaceae, Acinetobacter, Staphylococcus aureus, enterococci, and other streptococci were susceptible to imipenem. The majority of the strains of Pseudomonas aeruginosa (95%) and S. epidermidis (90%) were also inhibited. Nine of the 11 isolates of pseudomonads other than P. aeruginosa were resistant to this antibiotic. Imipenem. 1989; 9(3): 272-275 Imipenem (N-formimidoylthienamycin monohydrate) is a new thienamycin antibiotic produced by Streptomyces cattleya. Although it contains a beta-lactam ring, structurally, it is quite distinct from the penicillins, cephalosporins, and cephamycins. This unique structural difference of imipenem is apparently responsible for its having the broadest antimicrobial activity of currently available beta-lactam antibiotics and for its resistance to hydrolysis by chromosomal or plasmid-mediated beta-lactamases. SM Hussain Qadri, A Al-Hosain, In Vitro Susceptibility of Relatively Resistant Bacteria to

show abstract

Section: Accepted For Publication 25 September 1988mentioning

confidence: 99%

In Vitro Susceptibility of Relatively Resistant Bacteria to Imipenem

Qadri

Al-Hosain

1989

Ann Saudi Med

View full text Add to dashboard Cite

show abstract

“…A 10-hour session of slow HD gave a daily clear ance of 15.2 l/day for imipenem and 18.6 l/day for cilastatin. This efficacy was higher than that of conventional HD applied every other day [6], in conclusion, when 0.5/0.5 g of imipe nem/cilastatin was applied twice a day at the start and the end of each 10-hour session of slow HD. a therapeutic concentration of im ipenem was maintained without producing considerable accumulation of cilastatin.…”

Section: A Serial Application Study On Twice Daily Dose Of Imipenem/cmentioning

confidence: 67%

A Serial Application Study on Twice Daily Dose of Imipenem/Cilastatin in Patients Undergoing Slow Hemodialysis

Kihara

Ikeda

Shiratori³

et al. 1994

Nephron

View full text Add to dashboard Cite

“…Inherent assumptions and sources of error in each of the clearance measurements have been discussed previously (8). The clearance calculated by equation 1 would be accurate if the drug were removed only from the plasma, while equation 2 would be accurate if the complete and instantaneous concentration equilibrium were reached between the plasma and the erythrocyte water throughout the dialyzer. By equation 3 or 4, one can calculate hemodialysis clearance without knowing the intra-and extracellular distribution kinetics of the drug.…”

Section: Discussionmentioning

confidence: 99%

“…During concomitant drug therapy, the removal of a drug by hemodialysis may be significant enough to require a dosage supplement to ensure adequate therapeutic efficacy. The present study was conducted to evaluate the effect of hemodialysis on the pharmacokinetics of imipenem and cilastatin, since previous reports on this issue are limited in number and detail (1,4,11).…”

mentioning

confidence: 99%

Removal of imipenem and cilastatin by hemodialysis in patients with end-stage renal failure

Konishi

Suzuki

Saruta

et al. 1991

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The removal of nimpenem and cilastatin by hemodialysis was studied in 14 (for imipenem) and 6 (for cilastatin) subjects. FoUowing intravenous infusion of imipenem and cilastatin at a combined concentration of 10 mg/kg of body weight, drug levels in plasma were determined serially during off-and on-hemodialysis periods, which were 2 and 4 h, respectively. The biexponential decay of the drug levels in plasma was evident in each subject for both imipenem and cilastatin. Hemodialysis accelerated the elimination of both imipenem and cilastatin: the mean elimination-phase half-life of imipenem was shortened from 200 to 78 min, and that of cilastatin was shortened from 445 to 115 min. Hemodialysis clearance of imipenem and cilastatin was calculated by five different methods, each with intrinsic assumptions. The mean hemodialysis clearance of niipenem was estimated to be 74.08 + 13.29 ml/min, and that of cilastatin was estimated to be 65.0 + 8.6 ml/min, after consideration of various methodological limitations. It was estimated that in a hypothetical anephric patient weighing 60 kg, a 4-h hemodialysis treatment would remove 54.8% of the imipenem and 62.9% of the cilastatin present in the body at the start of dialysis.

show abstract

Multiple-dose study of imipenem/cilastatin in patients with end-stage renal disease undergoing long-term hemodialysis

Cited by 26 publications

References 4 publications

In Vitro Susceptibility of Relatively Resistant Bacteria to Imipenem

In Vitro Susceptibility of Relatively Resistant Bacteria to Imipenem

A Serial Application Study on Twice Daily Dose of Imipenem/Cilastatin in Patients Undergoing Slow Hemodialysis

Removal of imipenem and cilastatin by hemodialysis in patients with end-stage renal failure

Contact Info

Product

Resources

About